Scholar Rock Holding Corporation SRRK
Updated: 11 Sep 2026
No signal published yet
We already track Scholar Rock Holding and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Scholar Rock Holding Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Scholar Rock Holding free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On September 2, 2026, Scholar Rock received FDA Fast Track designation for its apitegromab program in facioscapulohumeral muscular dystrophy (FSHD) as participant dosing commenced in the Phase 2 FORGE trial. Additionally, the company is awaiting an FDA Prescription Drug User Fee Act (PDUFA) approval decision by September 30, 2026, for its Biologics License Application for apitegromab in spinal muscular atrophy.
What Firelda Watch includes for Scholar Rock Holding Corporation
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Scholar Rock Holding Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Scholar Rock Holding free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more